Anixa Biosciences secured a six-month exclusive right to negotiate a deal for VERDI's cancer vaccines. VERDI’s AI-driven platform develops personalized and off-the-shelf peptide vaccines for ...
On Tuesday, Anixa Biosciences, Inc. (NASDAQ:ANIX) entered into a letter of intent with VERDI Solutions GmbH to develop personalized and off-the-shelf peptide vaccines for cancer patients. VERDI ...
Research Institute of Hunan University in Chongqing, Chongqing 401120, China ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results